Implementation of High-Sensitivity Troponin I Starts in the Laboratory

Tuesday, August 6, 12:45 – 1:45 p.m.
Exhibit Hall, Theater 1
Supported by Siemens Healthineers

Overview

High-sensitivity cardiac troponin assays can play a critical role in the expedited diagnosis of acute myocardial infarction. Successful implementation of high-sensitivity troponin I starts in the laboratory. Learn about the keys to a successful transition, along with the latest HIGH-US clinical trial data documenting the performance of the Atellica® IM High-Sensitivity Troponin I (TnIH) Assay.

Outcomes

By the end of this session, attendees will:

  • Understand the importance of high-sensitivity troponin I.
  • Learn how to successfully implement high-sensitivity troponin I in your institution.
  • Learn about the robust HIGH-US clinical trial data that demonstrates the performance of the Atellica IM TnIH Assay.

Moderator

Melanie Pollan, Director
Scientific and Clinical Affairs
Siemens Healthineers
Athens, Georgia

Speakers

Alan Wu, PhD, DABCC, FACB, Chief
Clinical Chemistry and Toxicology Laboratories
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, CA

Robert H. Christenson, PhD, DABCC, FACB, Professor
Department of Pathology
University of Maryland, School of Medicine
Baltimore, MD